Business Context and Reporting Period
This Form 8-K is a current report filed by Iradimed Corporation on February 7, 2022. The report discloses a corporate action taken by the Board of Directors on February 5, 2022, regarding a special cash dividend.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The primary financial data point disclosed is the declaration of a special cash dividend of $1.00 per share on the Company's outstanding common stock.
Material Changes
The material event reported is the declaration of the special dividend. No comparative financial data or changes in operating metrics versus prior periods are included in this specific filing.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies beyond the standard legal disclaimers regarding the press release attached as Exhibit 99.1. The dividend is scheduled to be payable on February 24, 2022, to shareholders of record at the close of business on February 17, 2022.
Investor Verification Checklist
- Verify the record date of February 17, 2022, to confirm eligibility for the $1.00 per share special dividend.
- Confirm the payment date of February 24, 2022, for the dividend distribution.
- Review the attached press release (Exhibit 99.1) for any additional context regarding the rationale for the special dividend, as the 8-K text itself does not provide this.
- Note that the information in Item 8.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act.